Intercept ups guidance after Q2

 

• Ocaliva® (obeticholic acid or OCA) net sales of $83.7 million, representing 17% growth over the prior year quarter
• Company updates full-year 2023 Ocaliva net sales guidance to $320 million to $340 million; reiterates non-GAAP adjusted operating expense guidance of $350 million to $370 million
• Restructuring plan is on track to reduce operating expenses by approximately $140 million
• Company expects to achieve meaningful profitability in 2024
• OCA-bezafibrate combination making considerable progress; enrollment of both Phase 2 studies completed; Company expects to have necessary data to submit request in 2023 for End-of-Phase 2 meeting with FDA
• Company to host conference call today at 8:30 a.m. ET

The conference call and webcast discussing the Company’s second quarter 2023 financial results will take place on August 2, 2023, at 8:30 a.m. ET. The conference call will be available via a listen-only webcast on the investor page of our website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. A replay of the call will be available on our website shortly following the completion of the call and will be available for one year.

https://www.biospace.com/article/releases/intercept-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-business-updates/